TipRanks
Nektar Therapeutics (CH:NKTR)
:NKTR
Switzerland Market
NKTR
Nektar Therapeutics
RESEARCH TOOLSreports

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

NKTR Analyst Ratings

Strong Buy
11Ratings
Strong Buy
9 Buy
2 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Nektar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

―
Based on 11 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is CHF117.39 with a high forecast of CHF159.23 and a low forecast of CHF41.47. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF159.23Average Price TargetCHF117.39Lowest Price TargetCHF41.47
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on CH:NKTR
Samantha Semenkow
Citi
Citi
CHF125.23
Buy
―
Reiterated
10/05/26
Buy Rating Reaffirmed on Rezpeg’s Differentiated Profile; Price Target Maintained at $151
B. Riley Securities Analyst forecast on CH:NKTR
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
CHF124.4
Buy
―
Reiterated
10/02/26
B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
H.C. Wainwright Analyst forecast on CH:NKTR
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
CHF153.42
Buy
―
Reiterated
10/02/26
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (NASDAQ: SYRE), Sanofi (Other OTC: SNYNF) and Nektar Therapeutics (NASDAQ: NKTR)
William Blair Analyst forecast on CH:NKTR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
10/01/26
William Blair says rezpeg data a positive for NektarWilliam Blair says rezpeg data a positive for Nektar
Jefferies Analyst forecast on CH:NKTR
Roger Song
Jefferies
Jefferies
CHF124.4
Buy
―
Reiterated
10/01/26
Nektar selloff after rezpegaldesleukin data 'unwarranted,' says JefferiesNektar selloff after rezpegaldesleukin data 'unwarranted,' says Jefferies
BTIG Analyst forecast on CH:NKTR
Julian Harrison
BTIG
BTIG
CHF147.62
Buy
―
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: DocGo (NASDAQ: DCGO), Nektar Therapeutics (NASDAQ: NKTR) and Stryker (NYSE: SYK)
Canaccord Genuity Analyst forecast on CH:NKTR
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF126.89
Buy
―
Reiterated
09/28/26
Canaccord Genuity Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)
Wedbush Analyst forecast on CH:NKTR
Martin Fan
Wedbush
Wedbush
CHF66.35→CHF41.47
Hold
―
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nektar Therapeutics (NASDAQ: NKTR)
J.P. Morgan Analyst forecast on CH:NKTR
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF53.91
Hold
―
Initiated
08/21/26
Nektar reinstated with a Neutral at JPMorganNektar reinstated with a Neutral at JPMorgan
Piper Sandler Analyst forecast on CH:NKTR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF159.23
Buy
―
Reiterated
08/20/26
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
TD Cowen Analyst forecast on CH:NKTR
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/13/26
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
Oppenheimer Analyst forecast on CH:NKTR
Jay Olson
Oppenheimer
Oppenheimer
CHF116.1
Buy
―
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on CH:NKTR
Samantha Semenkow
Citi
Citi
CHF125.23
Buy
―
Reiterated
10/05/26
Buy Rating Reaffirmed on Rezpeg’s Differentiated Profile; Price Target Maintained at $151
B. Riley Securities Analyst forecast on CH:NKTR
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
CHF124.4
Buy
―
Reiterated
10/02/26
B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
H.C. Wainwright Analyst forecast on CH:NKTR
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
CHF153.42
Buy
―
Reiterated
10/02/26
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (NASDAQ: SYRE), Sanofi (Other OTC: SNYNF) and Nektar Therapeutics (NASDAQ: NKTR)
William Blair Analyst forecast on CH:NKTR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
10/01/26
William Blair says rezpeg data a positive for NektarWilliam Blair says rezpeg data a positive for Nektar
Jefferies Analyst forecast on CH:NKTR
Roger Song
Jefferies
Jefferies
CHF124.4
Buy
―
Reiterated
10/01/26
Nektar selloff after rezpegaldesleukin data 'unwarranted,' says JefferiesNektar selloff after rezpegaldesleukin data 'unwarranted,' says Jefferies
BTIG Analyst forecast on CH:NKTR
Julian Harrison
BTIG
BTIG
CHF147.62
Buy
―
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: DocGo (NASDAQ: DCGO), Nektar Therapeutics (NASDAQ: NKTR) and Stryker (NYSE: SYK)
Canaccord Genuity Analyst forecast on CH:NKTR
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF126.89
Buy
―
Reiterated
09/28/26
Canaccord Genuity Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)
Wedbush Analyst forecast on CH:NKTR
Martin Fan
Wedbush
Wedbush
CHF66.35→CHF41.47
Hold
―
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nektar Therapeutics (NASDAQ: NKTR)
J.P. Morgan Analyst forecast on CH:NKTR
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF53.91
Hold
―
Initiated
08/21/26
Nektar reinstated with a Neutral at JPMorganNektar reinstated with a Neutral at JPMorgan
Piper Sandler Analyst forecast on CH:NKTR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF159.23
Buy
―
Reiterated
08/20/26
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
TD Cowen Analyst forecast on CH:NKTR
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/13/26
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
Oppenheimer Analyst forecast on CH:NKTR
Jay Olson
Oppenheimer
Oppenheimer
CHF116.1
Buy
―
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
DFTXDefinium Therapeutics
HITIHigh Tide
DNLIDenali Therapeutics
MDWDMediwound
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

3 Months
Arthur He CFAH.C. Wainwright
Success Rate
8/19 ratings generated profit
42%
Average Return
+29.14%
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of +29.14% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
9/14 ratings generated profit
64%
Average Return
+169.09%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +169.09% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
9/14 ratings generated profit
64%
Average Return
+85.27%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +85.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
9
11
15
15
Buy
3
2
2
2
3
Hold
2
1
2
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
12
15
20
21
In the current month, NKTR has received 18 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 117.39.
Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -CHF1.74 with a range of -CHF2.55 to -CHF1.42. The previous quarter’s EPS was -CHF1.02. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.
Next quarter’s earnings estimate for NKTR is -CHF1.74 with a range of -CHF2.55 to -CHF1.42. The previous quarter’s EPS was -CHF1.02. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is CHF8.51M with a range of CHF7.91M to CHF9.12M. The previous quarter’s sales results were CHF8.40M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.
Next quarter’s sales forecast for NKTR is CHF8.51M with a range of CHF7.91M to CHF9.12M. The previous quarter’s sales results were CHF8.40M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Stock Forecast FAQ

What is CH:NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 117.39.
    What is CH:NKTR’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:NKTR, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Nektar Therapeutics a Buy, Sell or Hold?
        Nektar Therapeutics has a consensus rating of Strong Buy, which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Nektar Therapeutics’s share price target?
          The average share price target for Nektar Therapeutics is 117.39. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF159.23 ,and the lowest forecast is CHF41.47. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Nektar Therapeutics?
            Nektar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
              How can I buy shares of Nektar Therapeutics?
              To buy shares of CH:NKTR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.